Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFD-07 (Celecoxib) Cream in Actinic Keratosis
NCT03116698Phase 3Completed
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Feb 2017
- Primary completion
- Nov 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of celecoxib in actinic keratosis (AK) (4 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoint: Proportion of Subjects With Complete Clearance of AK Lesions at 16 weeks. Started Feb 2017; status: completed.
02
Drugs
celecoxib
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03116698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03116698.